Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement.

ABSTRACT: Drug hypersensitivity reactions (DHRs) to intravenous drugs can be severe and might leave patients and doctors in a difficult position where an essential treatment or intervention has to be suspended. Even if virtually any intravenous medication can potentially trigger a life-threatening DHR, chemotherapeutics, biologics, and antibiotics are amongst the intravenous drugs most frequently involved in these reactions. Admittedly, suspending such treatments may negatively impact the survival outcomes or the quality of life of affected patients. Delabeling pathways and rapid drug desensitization (RDD) can help reactive patients stay on first-choice therapies instead of turning to less efficacious, less cost-effective, or more toxic alternatives. However, these are high-complexity and high-risk

SUBMITTER: Alvarez-Cuesta E 

PROVIDER: S-EPMC9163606 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature